CD19 and autoimmune disease: Since altered expression of CD180 in autoimmune diseases and its potential pathological role in B cell activation and autoantibody production were already described [15–18], we measured CD180 expression at protein (mean fluorescence intensity (MFI)) and mRNA (RQ) levels in naïve (CD19+CD27−) and memory (CD19+CD27+) B cell subsets.